27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- The FDA has granted Emergency Use Authorization (EUA) to Ortho Clinical Diagnostics' (NASDAQ:OCDX) VITROS Anti-SARS-CoV-2 IgG Quantitative Test.
- The company says it the first quantitative COVID-19 IgG antibody test to receive a EUA nod.
- Ortho's new quantitative COVID-19 IgG antibody test targets the S1 spike protein and is intended for use in identifying individuals with an adaptive immune response to SARS-CoV-2.
- The test offers 100% specificity and excellent sensitivity, the company said in the press release.
- The new test is calibrated to the World Health Organization International Standard for anti-SARS-CoV-2 IgG antibodies.
- Price Action: OCDX shares closed at $21.32 on Friday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!